Free Trial

Chemed (CHE) Competitors

Chemed logo
$440.10 +9.18 (+2.13%)
Closing price 10/17/2025 03:59 PM Eastern
Extended Trading
$440.56 +0.46 (+0.11%)
As of 07:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CHE vs. MEDP, LH, DGX, DVA, CRVL, MD, AMN, CCRN, EHC, and ELAN

Should you be buying Chemed stock or one of its competitors? The main competitors of Chemed include Medpace (MEDP), Labcorp (LH), Quest Diagnostics (DGX), DaVita (DVA), CorVel (CRVL), Pediatrix Medical Group (MD), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), Encompass Health (EHC), and Elanco Animal Health (ELAN).

Chemed vs. Its Competitors

Chemed (NYSE:CHE) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

In the previous week, Medpace had 13 more articles in the media than Chemed. MarketBeat recorded 19 mentions for Medpace and 6 mentions for Chemed. Chemed's average media sentiment score of 1.58 beat Medpace's score of 0.97 indicating that Chemed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Chemed
5 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Medpace
13 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

95.9% of Chemed shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 20.3% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Medpace has lower revenue, but higher earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chemed$2.43B2.64$302M$19.4522.63
Medpace$2.11B7.03$404.39M$13.4539.26

Medpace has a net margin of 18.74% compared to Chemed's net margin of 11.56%. Medpace's return on equity of 67.66% beat Chemed's return on equity.

Company Net Margins Return on Equity Return on Assets
Chemed11.56% 25.83% 17.77%
Medpace 18.74%67.66%21.86%

Chemed has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Chemed presently has a consensus target price of $578.50, indicating a potential upside of 31.45%. Medpace has a consensus target price of $430.60, indicating a potential downside of 18.46%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than Medpace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chemed
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Medpace
3 Sell rating(s)
12 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.94

Summary

Medpace beats Chemed on 9 of the 16 factors compared between the two stocks.

Get Chemed News Delivered to You Automatically

Sign up to receive the latest news and ratings for CHE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CHE vs. The Competition

MetricChemedMED IndustryMedical SectorNYSE Exchange
Market Cap$6.41B$4.32B$6.13B$21.77B
Dividend Yield0.54%1.24%5.72%3.63%
P/E Ratio22.6330.1629.3432.43
Price / Sales2.64287.68595.2781.20
Price / Cash17.1428.2625.8218.06
Price / Book5.924.7712.224.59
Net Income$302M$197.51M$3.33B$1.01B
7 Day Performance2.54%4.04%0.62%-0.38%
1 Month Performance-2.67%5.94%6.82%-0.93%
1 Year Performance-27.87%28.02%58.78%9.46%

Chemed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CHE
Chemed
4.9836 of 5 stars
$440.10
+2.1%
$578.50
+31.4%
-27.9%$6.41B$2.43B22.6315,695Positive News
MEDP
Medpace
4.2815 of 5 stars
$527.40
+5.2%
$422.27
-19.9%
+48.2%$14.08B$2.11B39.215,900Upcoming Earnings
Analyst Forecast
LH
Labcorp
4.4157 of 5 stars
$276.37
-0.5%
$292.00
+5.7%
+32.4%$23.09B$13.01B30.5070,000Positive News
Analyst Forecast
DGX
Quest Diagnostics
4.6902 of 5 stars
$182.81
-0.7%
$186.63
+2.1%
+26.8%$20.58B$9.87B21.8956,000Positive News
Upcoming Earnings
Analyst Forecast
DVA
DaVita
4.8808 of 5 stars
$123.89
-0.1%
$155.25
+25.3%
-22.3%$8.87B$12.82B12.1876,000
CRVL
CorVel
1.0777 of 5 stars
$71.41
-1.7%
N/A-31.4%$3.73B$895.59M36.815,075
MD
Pediatrix Medical Group
1.5301 of 5 stars
$16.06
+1.6%
$16.79
+4.5%
+29.3%$1.38B$2.01B12.454,305
AMN
AMN Healthcare Services
4.3398 of 5 stars
$19.14
+5.4%
$23.08
+20.6%
-52.1%$695.97M$2.98B-2.462,968Short Interest ↓
Analyst Revision
CCRN
Cross Country Healthcare
3.8023 of 5 stars
$12.50
+7.9%
$17.93
+43.4%
-1.9%$379.71M$1.34B-48.088,205
EHC
Encompass Health
4.8307 of 5 stars
$121.35
-0.7%
$139.86
+15.2%
+28.2%$12.30B$5.37B23.7540,000
ELAN
Elanco Animal Health
2.5557 of 5 stars
$20.04
+1.4%
$19.14
-4.5%
+65.2%$9.82B$4.44B23.309,000

Related Companies and Tools


This page (NYSE:CHE) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners